Merck Splits Oncology Business Unit as Keytruda Patent Expiry Nears / OncoDaily

oncodaily - On February 23, 2026, Merck announced a reorganization of its Human Health structure into two business units: an Oncology Business Unit and a Specialty, Pharma & Infectious Diseases Business Unit. […]

#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology #healthcarefinance

Merck KGaA drops two cancer trials on assets from SpringWorks deal

11 days / endpoints / Reynald Castaneda

No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC

13 days / esmo

Cancer Research UK partners with the Royal College of Surgeons of England to help people with rectal cancer avoid unnecessary surgery

13 days / cancerresearchuk / Krishna Sharma

A domain-adaptive deep contrastive network for magnetic resonance imaging-driven bladder cancer classification

14 days / nature

Multicenter ex vivo evaluation of an α-mannosidase–targeted fluorescent probe for intraoperative margin assessment in breast cancer

14 days / nature

Neoadjuvant pembrolizumab plus chemotherapy in older patients with early-stage triple-negative breast cancer: real-world insights from neo-real/GBECAM-0123

14 days / nature

Merck looks to expand Welireg label following combo readouts with Keytruda, Lenvima

16 days / endpoints / Nicole DeFeudis

Merck Splits Oncology Business Unit as Keytruda Patent Expiry Nears

18 days / oncodaily

Merck reorganizes; Blackstone to fund trials for J&J drug

21 days / endpoints / ENDPOINTS

Saturday, February 28, 2026, 3:22 am / permalink 19937 / 9 stories in 16 days

Related Stories

Related Tags

Healthcare

HIMSS 2026 pushes real‑time data, cloud and interoperability playbook (16 hrs)

Neoadjuvant GOLP improves event‑free survival in high‑risk intrahepatic cholangiocarcinoma (17 hrs)

Vitamin D trial shows reduced long‑COVID risk but no severity benefit (19 hrs)

more #healthcare

Pharmaceuticals

Neoadjuvant GOLP improves event‑free survival in high‑risk intrahepatic cholangiocarcinoma (17 hrs)

Atezolizumab added to chemoradiation fails to improve limited‑stage SCLC survival (20 hrs)

FDA approves leucovorin for rare folate disorder despite autism hype (32 hrs)

more #pharmaceuticals

Biotech

Neoadjuvant GOLP improves event‑free survival in high‑risk intrahepatic cholangiocarcinoma (17 hrs)

Atezolizumab added to chemoradiation fails to improve limited‑stage SCLC survival (20 hrs)

HORMAD1 emerges as a potential target in triple‑negative breast cancer (45 hrs)

StackHealth Time Machine

NorthFeed Inc.

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.